Related Experiment Video
Updated: Jun 18, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
[Baicalein selectively induce apoptosis in human leukemia K562 cells]
Qing-hua Dong1, Shu Zheng, Rong-zhen Xu
1Cancer Institute, Second Affiliated Hospital, Zhejiang University, Hangzhou 310009, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|March 3, 2004
Summary
Baicalein effectively inhibits human leukemia K562 cell proliferation and induces apoptosis. This occurs through increased expression of Fas and Caspase-3, offering a potential therapeutic strategy for leukemia.
Area of Science:
- Pharmacology
- Molecular Biology
- Cancer Research
Context:
- Human leukemia K562 cells are a common model for studying leukemia.
- Baicalein is a flavonoid with potential anticancer properties.
- Understanding the mechanism of action of natural compounds is crucial for drug development.
Purpose:
- To investigate the antitumor effects of baicalein on human leukemia K562 cells.
- To elucidate the underlying molecular mechanisms of baicalein-induced apoptosis.
Summary:
- Baicalein significantly inhibits K562 cell proliferation in a dose-dependent manner.
- Baicalein induces apoptosis in K562 cells and arrests them in the S phase.
- Baicalein up-regulates the expression of Fas and Caspase-3, while Bcl-2 expression remains unchanged.
Impact:
- Baicalein demonstrates selective antitumor activity against human leukemia K562 cells.
- The findings suggest baicalein as a potential therapeutic agent for leukemia.
- This study provides insights into the apoptotic pathways modulated by baicalein.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...